患者报告结局指标在乳腺癌放疗中的敏感性研究
该前瞻性研究纳入414例接受光子外照射放疗的乳腺癌患者,使用自研PROM工具评估副作用,比较全乳放疗(40 Gy)、全乳放疗加序贯推量(10 Gy)及部分乳腺放疗(40 Gy)组间报告毒性的差异。结果显示加推量组在瘙痒、放射性皮肤反应、皮肤变暗及压痛肿胀方面与无推量全乳放疗组存在显著差异,部分乳腺放疗与无推量全乳放疗在放射性皮肤反应方面存在显著差异。结论强调PROM对治疗相关副作用的检测具有高敏感性,可能作为质量控制和基于真实世界数据循证学习的有价值工具。
要点
- 414例乳腺癌患者接受PROM评估,其中全乳放疗128例(31%)、全乳加序贯推量241例(58%)、部分乳腺放疗50例(12%)。
- 全乳加推量组与无推量全乳放疗组在瘙痒、放射性皮肤反应、皮肤变暗、压痛肿胀方面差异显著(p分别<0.001、<0.001、<0.001、0.002)。
- 部分乳腺放疗与无推量全乳放疗在放射性皮肤反应方面差异显著(p<0.001)。
核心结论
- PROM对检测乳腺癌放疗患者的治疗相关副作用具有高敏感性。
- PROM可能作为质量控制和基于日常常规诊疗真实世界数据循证学习的有价值工具。
研究设计与样本
- 前瞻性研究,纳入2020年10月至2022年1月期间接受光子外照射放疗的乳腺癌患者414例。
- 作为日常临床诊疗的一部分,使用自研PROM工具评估患者副作用。
- 患者接受全乳放疗至40 Gy、全乳放疗加序贯推量10 Gy或部分乳腺放疗至40 Gy。
主要发现
- 414例患者中,128例(31%)接受全乳放疗,241例(58%)接受全乳放疗加序贯推量,50例(12%)接受部分乳腺放疗。
- 全乳加推量组与无推量全乳放疗组在瘙痒(p<0.001)、放射性皮肤反应(p<0.001)、皮肤变暗(p<0.001)、压痛肿胀(p=0.002)方面报告毒性存在显著差异。
- 部分乳腺放疗与无推量全乳放疗比较,在放射性皮肤反应方面存在显著差异(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the sensitivity of patient-reported outcome measures (PROMs) to detect treatment-related side effects in patients with breast cancer undergoing external beam photon radiotherapy. METHODS: As part of daily clinical care, an in-house developed PROM tool was used to assess side effects in patients during a) whole-breast irradiation (WBI) to 40 Gy, b) WBI with a sequential boost of 10 Gy, and c) partial-breast irradiation (PBI) to 40 Gy. RESULTS: 414 patients participated in this prospective study between October 2020 and January 2022, with 128 patients (31 %) receiving WBI, 241 (58 %) receiving WBI followed by a sequential boost, and 50 patients (12 %) receiving PBI. Significant differences in the reported toxicities (itching, radiation skin reaction, skin darkening, and tenderness and swelling) were reported between the WBI cohorts with and without boost (p < 0.001, p < 0.001, p < 0.001, and p = 0.002, respectively). The comparison of PBI with WBI (no-boost) yielded significant differences for radiation skin reaction (p < 0.001). CONCLUSION: The results highlight the high sensitivity of PROMs to detect treatment-related side effects in patients with breast cancer. Thus, PROMs may be a valuable tool for quality control and may support evidence-based learning from real-world data originating from daily routine care.
引用
- Heilemann G, Renner A, Kauer-Dorner D, et al. On the sensitivity of PROMs during breast radiotherapy. Clin Transl Radiat Oncol. 2022. PMID: 36632055. doi:10.1016/j.ctro.2022.100572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。